Role of 99mTc-pyrophosphate myocardial scintigraphy in assessing the efficiency of tafamidis therapy: a case series
https://doi.org/10.15829/1560-4071-2025-6200
EDN: XSICKB
Abstract
Introduction. In recent years, the detection rate of transthyretin amyloid cardiomyopathy has been rapidly increasing. The only drug registered as a pathogenetic therapy in Russia is tafamidis. To date, there is no single protocol for assessing disease progression, and the role of scintigraphy with phosphate complexes is not reflected in current documents due to the lack of evidence.
Brief description. The article presents a case series including patients who received tafamidis therapy for at least 12 months. During therapy, there were no signs of disease progression, and in some cases, according to myocardial scintigraphy with phosphate complexes, a decrease in radiopharmaceutical uptake was noted.
Discussion. The role of myocardial scintigraphy with phosphate complexes for monitoring the effectiveness of tafamidis therapy was discussed.
About the Authors
A. A. Shoshina
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
A. A. Ansheles
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
S. N. Nasonova
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
I. V. Zhirov
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
V. B. Sergienko
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
S. N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
References
1. Nikiforova TV, Charaya KV, Shchekochikhin DYu, et al. Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia. Kardiologiia. 2024;64(4):54-60. (In Russ.) doi:10.18087/cardio.2024.4.n2611.
2. Nasonova SN, Zhirov IV, Shoshina AA, et al. Expert Center for cardiac amyloidosis: reality and perspectives. Terapevticheskii arkhiv. 2024;96(4):321-9. (In Russ.) doi:10.26442/00403660.2024.04.202677.
3. Khor YM, Cuddy SAM, Singh V, et al. 99mTc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis. Radiology. 2023; 306(2):e221082. doi:10.1148/radiol.221082.
4. Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277-85. doi:10.1002/ejhf.2027.
5. Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895-905. doi:10.1002/ejhf.2198.
6. Garcia-Pavia P, Aus dem Siepen F, Donal E, et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023;389(3):239-50. doi:10.1056/NEJMoa2303765.
7. Odouard S, Abulizi M, Kharoubi M, et al. Tafamidis Decreases Cardiac Uptake of 99mTc-HMDP in Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15(12): 2149-51. doi:10.1016/j.jcmg.2022.06.013.
8. Yu AL, Chen YC, Tsai CH, et al. Tafamidis Treatment Decreases 99mTc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy. JACC Cardiovasc Imaging. 2023;16(6):866-7. doi:10.1016/j.jcmg.2022.12.016.
Supplementary files
- Patients with transthyretin amyloid cardiomyopathy are indicated for taking the selective transthyretin stabilizer tafamidis.
- During therapy, monitoring for disease progression is necessary.
- A case series demonstrates the importance of myocardial scintigraphy as a tool in assessing disease progression and demonstrates a previously undescribed effect of therapy in reducing the myocardial radiopharmaceutical uptake.
Review
For citations:
Shoshina A.A., Ansheles A.A., Nasonova S.N., Zhirov I.V., Sergienko V.B., Tereshchenko S.N. Role of 99mTc-pyrophosphate myocardial scintigraphy in assessing the efficiency of tafamidis therapy: a case series. Russian Journal of Cardiology. 2025;30(1):6200. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6200. EDN: XSICKB
Views:
176
Email this article 